| Lymphocytes (%) | B cells (%) |
---|
Characteristics | CD19+ | CD27+ | CD27+IgD+ | CD27+IgD- | CD27-IgD+ | CD27-IgD- |
---|
RA duration, yr | -0.23b | -0.11 | -0.10 | -0.13 | 0.07 | 0.08 |
Steroid dose, mg/day | -0.06 | 0.25c | 0.20 | 0.27c | -0.23b | 0.16 |
TNFi agents used (n) | -0.16 | -0.15 | -0.07 | -0.17 | 0.16 | -0.21b |
DAS28 score | 0.03 | 0.10c | 0.18c | 0.02 | -0.10 | -0.04c |
- aDAS28, Disease Activity Score in 28 joints; Ig, Immunoglobulin; RA, Rheumatoid arthritis; TNFi, Tumor necrosis factor inhibitor. bP < 0.05, cP < 0.01. cCorrelations were not significant; however CD27+, CD27+IgD+ and CD27-IgD- proportions were higher in patients with active RA than in those with low disease activity after adjustment for age, sex and steroid dose (general linear models). Data are Spearman’s r statistics.